Hanne Lamberink, Sammy Huygens, Robina Aerts, Katrien Lagrou, Elena van Leeuwen-Segarceanu, Tom Lodewyck, Laurens Nieuwenhuizen, Maarten F Corsten, Ine Moors, Sophie Servais, Julien De Greef, Maya Hites, Astrid Demandt, Alexander Schauwvlieghe, Johan Maertens, Bart Rijnders
{"title":"Superiority trials in invasive aspergillosis: a harsh reality check with the IA-DUET (HOVON502) trial","authors":"Hanne Lamberink, Sammy Huygens, Robina Aerts, Katrien Lagrou, Elena van Leeuwen-Segarceanu, Tom Lodewyck, Laurens Nieuwenhuizen, Maarten F Corsten, Ine Moors, Sophie Servais, Julien De Greef, Maya Hites, Astrid Demandt, Alexander Schauwvlieghe, Johan Maertens, Bart Rijnders","doi":"10.1093/cid/ciae501","DOIUrl":null,"url":null,"abstract":"The IA-DUET study aimed to compare azole-echinocandin combination with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":8.2000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cid/ciae501","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The IA-DUET study aimed to compare azole-echinocandin combination with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.
期刊介绍:
Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.